![Sharon Longhurst](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sharon Longhurst
Direktor/Vorstandsmitglied bei IDOGEN AB (PUBL)
Aktive Positionen von Sharon Longhurst
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IDOGEN AB (PUBL) | Direktor/Vorstandsmitglied | 12.05.2020 | - |
Independent Dir/Board Member | 12.05.2020 | - | |
ELICERA THERAPEUTICS AB | Direktor/Vorstandsmitglied | 01.01.2024 | - |
Independent Dir/Board Member | 01.01.2024 | - |
Karriereverlauf von Sharon Longhurst
Ehemalige bekannte Positionen von Sharon Longhurst
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Corporate Officer/Principal | 01.10.2021 | 01.08.2023 |
MENDUS AB | Corporate Officer/Principal | - | - |
Ausbildung von Sharon Longhurst
University of Warwick | Doctorate Degree |
University of Surrey | Undergraduate Degree |
Statistik
International
Schweden | 4 |
Vereinigtes Königreich | 3 |
Niederlande | 2 |
Operativ
Director/Board Member | 2 |
Independent Dir/Board Member | 2 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
IDOGEN AB (PUBL) | Health Technology |
MENDUS AB | Health Technology |
ELICERA THERAPEUTICS AB | Health Technology |
Private Unternehmen | 1 |
---|---|
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
- Börse
- Insiders
- Sharon Longhurst
- Erfahrung